Who should read the Guide?
The Guide
should be particularly useful for pharmaceutical business development people
and executives as well as investors in the public stock markets (esp. biotech)
in order to gain a broader understanding of the technical, regulatory, and
economic context of RNAi Therapeutics drug development. Investment opportunities and related risks
will become apparent.
Specifically,
the Guide
a) Recaps the most important technical, clinical, capital markets,
and business development events
related to RNAi Therapeutics in 2013 leading up to a snapshot of the current industry status. This includes putting these topics in the
context of broader economic and regulatory trends as well as the field of
Oligonucleotide/RNA Therapeutics;
b) Provides an outlook on 2014,
particularly a discussion of important RNAi Therapeutics product candidates and upcoming clinical read-outs in 2014. In addition, it will give a sense of how the year may play out in
the capital markets (business development
and stock markets) in more general terms;
c) Discusses strategies and valuations
of key RNAi Therapeutics players, including Alnylam, Arrowhead Research, Benitec,
Dicerna, Marina Biotech, RXi Pharmaceuticals, and Tekmira.
~30 pages (as pdf email attachment)
Pricing
Drug development companies up to 10 employees: 500 Euros/650 US
dollars
Drug development companies over 10 employees: 1000 Euros/1300 US
dollars
Other companies (e.g. financial institutions and investment
funds): 800 Euros/1100 US dollars
University libraries: 95 Euros/130 dollars
Individuals (private use only): 140 Euros/ 195 US dollars
Prices exclude 19% VAT for German customers (corporate and
non-corporate) and non-corporate customers in the European Union.
Payments either by check, bank transfer or paypal.
Payments either by check, bank transfer or paypal.
When ordering, the following information is required:
Full name and address
Use (corporate, individual etc)
Billing name and address if different
Order by contacting me at myfirstname.mylastnameATgmail.com
My first name: dirk; my last name: haussecker
My first name: dirk; my last name: haussecker
Dirk, if I were to order a copy would I get to read about endosomal escape hatch technology? And who it is that is blazing a trail in this area?
ReplyDeleteI'm afraid not really.
ReplyDeleteDirk, you should help Marina Biotech discover a polymer delivery system so they could be the one stop shop for oligo therapeutics!
ReplyDeleteIt is time for a new poll for 2014...
ReplyDeleteWell, the answer would be already known for that...Sanofi/Genzyme.
ReplyDeleteI hope this one is on your list.
ReplyDeleteBLT's ddRNAi coming in to play yet again.
Gene therapy biopharma uniQure sets terms for $64 million IPO
1/24/14
uniQure, which develops gene therapies for the treatment of orphan diseases, announced terms for its IPO on Friday. The Amsterdam, Netherlands-based company plans to raise $64 million by offering 4.6 million shares at a price range of $13 to $15. At the midpoint of the proposed range, uniQure would command a market value of $235 million.
uniQure, which was founded in 1998 and booked $3 million in license and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol QURE. uniQure initially filed confidentially on November 8, 2013. Jefferies, Leerink Partners and Piper Jaffray are the joint bookrunners on the deal
Thanks for the Guide
ReplyDelete